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Abstract
Background—Diabetic nephropathy is the main cause of end-stage renal disease and has 
reached epidemic proportions.
Methods—Comprehensive genomic profiling (RNA Seq) was employed in the ZS (F1 hybrids of 
Zucker and spontaneously hypertensive heart failure) model of diabetic nephropathy. Controls 
were lean littermates.
Results—Diabetic nephropathy in obese, diabetic ZS was accelerated by a single episode of 
renal ischemia (DI). This rapid renal decline was accompanied by activation of the renal 
complement system in DI, and to a lesser extent in sham operated diabetic rats (DS). In DI there 
were significant increases in renal mRNA encoding C3, C4, C5, C6, C8 and C9 over sham 
operated lean normal controls (LS). Moreover, mRNAs encoding the receptors for the 
anaphylatoxins C3a and C5a were also significantly increased in DI compared to LS. The classic 
complement pathway was activated in diabetic kidneys with significant increases of C1qa, C1qb, 
and C1qc mRNAs in DI over LS. In addition, critical regulators of complement activation were 
significantly attenuated in DI and DS. These included mRNAs encoding CD55, decay accelerating 
factor, and CD59, which inhibits the membrane attack complex. C3, C4 and C9 proteins were 
demonstrated in renal tubules and glomeruli. The complement RNAseq data were incorporated 
into a gene network showing interactions among C3 generating renal tubular cells and other 
immune competent migratory cells.
Conclusions—We conclude that local activation of the complement system mediates renal 
injury in diabetic nephropathy.
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INTRODUCTION
Diabetic nephropathy is the main reason for the vast numbers of patients entering end-stage 
renal disease (ESRD) programs [1]. Unfortunately, current therapies of diabetic nephropathy 
fail to stop progression to ESRD [2]. To gain insight into its progressive pathophysiology, 
we have studied diabetic nephropathy in the ZS rat, a model of obesity and diabetes that 
progresses to ESRD [3], with features similar to human diabetic nephropathy [4, 5]. ZS rats 
suffer an accelerated decline following renal ischemia with associated inflammation. These 
renal responses include leukocyte infiltration and broad activation of pro-inflammatory 
genes [6]. We hypothesized that this complexity can be dissected by systems biology, and 
used deep sequencing with advanced bioinformatics tools to study disease mechanisms of 
diabetic nephropathy [7]. We found that obese, diabetic rats with renal ischemia exhibited 
general and prominent activation of the renal complement system along with interacting pro-
inflammatory gene networks. The complement system is a mainstay of systemic innate 
immunity comprising several interacting components [8]. The master element is 
complement component 3 (C3), which is in a perpetual state of contained activity [9], 
restrained by specific proteins [8, 9]. Failure of the regulatory proteins leads to uncontrolled 
activation and injury [8].
The presence of renal C3 in human diabetic nephropathy was reported from the beginning of 
immunofluorescence, but was thought secondary to non-specific trapping of plasma C3 [10]. 
Experiments on diabetic animals also found renal C3; and again, it was thought to be blood-
derived [11]. In our studies of renal transcriptomes in diabetes (7) we found major activation 
of the renal complement system in rats with diabetic nephropathy.
SUBJECTS and METHODS
Animals
The three groups of rats included here, and their core renal transcript networks, including 
inflammation, have been reported elsewhere [7]. Lean and obese, diabetic male ZS rats 
(Charles River, Wilmington, MA) were acquired at 8 weeks of age and fed Purina diet 
#5008. Their body weights were measured and sera plus urine samples analyzed at biweekly 
intervals. One group of obese/diabetic rats was subjected to bilateral renal ischemia at 10 
weeks of age as described (DI, n=11) [7]. The lean rats (LS, n=6) and a second obese/
diabetic group (DS, n = 7) were subjected to sham surgery. These rats were terminated at 28 
weeks of age, their kidneys removed, immediately frozen in liquid nitrogen, and RNA 
extracted (below). In addition, renal tubular cells from 12 week-old normal Sprague Dawley 
male rats (n=4) were isolated as previously described [12].
Histology and immunohistochemistry
Kidney sections were stained for histology and changes quantified in blinded sections as 
described [7, 10]. Immunostaining was performed as described [10] using goat anti-
complement component 3 (CAT #c312-A, Alpha Diagnostics, San Antonio, TX), rabbit 
anti-complement component 4 (CAT #hp8023, Hycult Biotech, Plymouth Meeting, PA) and 
mouse anti-complement component 9 (CAT #ab17931, Abcam, Cambridge, MA) and then 
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Texas Red-conjugated donkey anti-rabbit (CAT# 111-075-045, Jackson ImmunoResearch, 
West Grove, PA) secondary antibody.
Hypoxia chamber
Kidney tubular cells, derived from normal Sprague Dawley rats [10] were grown in 
38%O2/5%CO2 until confluent and then subjected to anoxia (1%O2/5%CO2 in a hypoxia 
chamber [Hypoxia workstation, Sci-Tive-Dual, Ruskinn Technology, Bridgend, UK]) for 
periods of 8–48 hours ("ischemia”). The cells were then switched back to 38%O2/5%CO2 
for 16–24 more hours (“reperfusion”). Control cells were always maintained in 
38%O2/5%CO2. Total RNA were isolated from these cells and mRNAs encoding C3, C4, 
C5, C8, C9 were measured by RT2PCR.
RNA-seq and RT2PCR
Total kidney RNA isolation was performed as described [7].. RNA, 3 ug, was fragmented 
with RNAase III, cDNA libraries constructed with SOLiD adaptors by reverse transcription 
(RT), and then sequenced by strand specific RNA-seq of short 50 bp reads using the SOLiD 
4 platform (Center for Medical Genomics at Indiana University School of Medicine) as 
described [7]. Sequence alignment to the UCSC rat genome database was performed using 
BFAST [13]. Gene expression was calculated in the form of Reads per Kilobase Exon 
Model per million mapped reads (RPKM) [14]. To identify differentially expressed genes, 
we conducted student t-test on the logarithmically transformed RPKM values, comparing DI 
vs. LS and DS vs. LS. Network analysis was performed using Metacore Software (GeneGo, 
Carlsbad, CA).
RT2PCR was performed [7] using primers from Qiagen, Valencia, CA. The samples were 
run in quadruplicate, normalized to β-actin mRNA and are reported as amount of mRNA 
compared to control samples [15].
Animal Use Statement
The experiments were conducted in conformity with the "Guiding Principles for Research 
Involving Animals and Human Beings." The investigations were approved by the 
Institutional Animal Care and Use Committee of Indiana University School of Medicine.
Statistics
Results are expressed as means ± 1 standard error. Differences in renal and metabolic 
parameters were determined by 1 way ANOVA with subsequent t-tests (when ANOVA 
indicated statistical significance, GraphPad Prism, LaJolla, CA). Bonferroni correction was 
used for multiple comparisons. The null hypothesis was rejected at p<0.05.
RESULTS and DISCUSSION
The abnormal metabolic and renal phenotypes in the ZS rats included in this report were 
described in more detail in an earlier article [7]. There were 3 groups of ZS rats: lean sham-
operated (LS), obese/diabetic sham-operated (DS), and obese/diabetic subjected to a short 
period of bilateral renal ischemia (DI). At termination, DS and DI rats were heavier, 539±28 
Kelly et al. Page 3
Am J Nephrol. Author manuscript; available in PMC 2016 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and 526±26 than the LS controls, 466±67 (weight in gm p < 0.05 for both). The blood 
glucose levels were also higher in DS and DI, 29.4±16 and 30.5±1.7, respectively, when 
compared to LS controls, 7.8±0.6 (glucose in mM, significantly higher for both, p < 0.05). 
Creatinine clearance rates were also depressed in DS and DI rats when compared to LS 
controls (figure 1). Proteinuria, normal in LS, was increased 27 and 30 fold in DS and DI, 
respectively [7]. Renal histology in ZS rats included the following stains: Leder’s stain to 
identify leukocytes, PAS to outline cell structure and extracellular matrix, and Mason’s 
trichrome to label fibrosis, figure 1. Leder’s stain in DS and DI rats revealed clusters of 
densely packed cellular infiltrates that contained neutrophils. PAS demonstrated increases in 
tubular damage plus interstitial and glomerular extracellular matrix, particularly in the DI 
rats (vs LS). Trichrome stain showed early stages of peritubular fibrosis in DS rats, and 
more advanced in DI rats (vs LS), figure 1.
Renal histology revealed the stark complexity of diabetic nephropathy; migrating 
inflammatory cells could be found in the vicinity of stressed and damaged renal epithelial 
and endothelial cells. These intricate relations were approached by systems biology, and we 
analyzed the interactions among expressed renal transcriptomes in the three conditions: LS, 
DS, and DI. Among the many up-regulated renal transcripts in diabetic nephropathy [7], a 
subset of stimulated mRNAs stood out because it contained most elements of the 
complement system. The up-regulation of these transcripts is shown on the top in figure 2a. 
We verified these RNAseq results with RT2PCR as an independent measurement. The 
correlations of mRNA results obtained between the two methods, RNAseq and RTPCR, 
were excellent and are shown in figure 2b.
The renal protein expression of the complement components C3, C4, and C9 was then 
examined by immunofluorescence. There was very faint expression of these proteins in LS 
rats. However in DS, and particularly in DI, C3, C4, and C9 were broadly expressed in renal 
tubules and glomeruli. C3, nearly absent in lean group glomeruli (LS), was robustly 
expressed in diabetes/sham (DS) and more so in diabetes/ischemia (DI) kidneys, figure 3.
The kidney has been viewed as a passive target of circulating complement components of 
hepatic origin which result in immune complex-mediated glomerular injury. It is now 
recognized that vast local expansion of complement can occur in injured kidneys [16] and, 
in animal models, can affect progression of renal failure and survival [17]. Our data showing 
increased expression of complement components in the renal transcriptome are consistent 
with local complement activation in diabetic nephropathy. To test the hypothesis that C3 is 
derived from the tubular epithelium and that ischemia is a critical mediator of the C3 
production, primary cultures of normal Sprague Dawley rat renal tubular cells were exposed 
to acute anoxic conditions, followed by re-oxygenation, i.e., in vitro “ischemia/reperfusion.” 
Following anoxia, mRNA encoding C3 was markedly elevated, 2.34 ± 0.05 fold over 
normoxic cells (p<0.05; n=4), while mRNAs encoding C1, C3, C5, C8, and C9 were slightly 
depressed (not shown). C3 protein was also increased by anoxia (figure 3). In addition to 
ischemia, inflammatory cytokines and loss or decrease in regulatory proteins have been 
shown important in local complement expression [18, 19].
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Transcripts of the complement system were assembled in a gene network (figure 4). These 
transcripts were differentially expressed in both conditions, DS and DI, when compared to 
controls (LS). The center piece of the network is complement component C3 (C3); activated 
5.2 fold in chronic diabetic nephropathy with ischemia over lean rat controls, and 2.3 fold 
after 24 hours of acute anoxia/reoxygenation in isolated renal tubular cells. These results 
confirm intrinsic renal expression of C3, as previously suggested [20, 21]. C3b, derived 
from up-regulated renal C3, generates the classical pathway C5 convertase (C4bC2aC3b) 
that cleaves C5. Renal C5 and C5aR1 mRNAs were not among the 13,453 detected and 
measured renal transcripts reported by RNAseq, and we resorted to RT2-PCR to measure 
these transcripts in the three groups of rats: C5 mRNA in DS and DI was 58% and 35% 
higher than in LS (p<0.03). C5aR1 mRNA in DS and DI were 2.2 fold (p<0.07) and 3.4 fold 
higher than LS (p <0.04). The C1 complex was well represented in the RNAseq analysis, 
with up-regulation of C1q, C1s, and C1r, and C2. In the network, C1q is acting on C2 and 
C4, forming the C3 convertase (C4bC2a), leading to the assembly of the classical pathway 
C5 convertase, C4bC2aC3b [9]. C1q also stimulates the release of interleukin-12 (IL-12) 
[22], also activated by other components (below), and the pro-inflammatory homing 
receptor CCR7, which enhances the effects of its up-regulated ligand, CCL19 via PI3K [23].
CD55, or decay accelerating factor (DAF), is restricted to cell membranes [24] where it 
antagonizes both C3 and C5 convertases. This transcript encodes a critical controller of 
activation, and it is suppressed in kidneys from DI rats 35% (p<0.004). The attenuation of 
renal DAF may cede the modulatory role to up-regulated complement factor I (CFI) [25] 
(increased 10.5 fold, p=1.25×105) and complement factor H (CFH) [26] (increased 1.8 fold, 
p<0.002). However, the up-regulation of CFI and CFH failed to prevent complement 
activation. It is likely that complement was activated by up-regulation of complement factor 
D (CFD) and unchanged factor B (CFB) that cause the formation of the C3 amplification 
convertase C3bBb [27]. These events lead to the formation of the membrane attack complex 
(MAC). The cytotoxic activity of MAC in diabetic nephropathy was further enhanced by the 
attenuation of CD59, which promotes the clearance of MAC [28]. Renal C3 activation 
generates the anaphylatoxins C3a and C5a, and the portal for C3a, the receptor C3ar1, is 
also up-regulated in diabetic nephropathy. Activated CD80 (or B7-1), the receptor for 
cytotoxic T lymphocyte antigen 4 (CTLA4), is a downstream target for C3a [29]. C3a and 
C5a both act on unchanged renal extracellular signal-regulated kinases 1/2 (ERK), in accord 
with a role for ERK signaling in complement activation [30–32]. IL-12 is another 
downstream target for activated C3a [33][36] and C5a [34]. The network also shows C3a 
acting on ICAM-1, a relationship previously reported [35]. C3a also modulates T cell 
maturation [37]. The importance of the renal IL-12 gene in diabetic nephropathy is further 
emphasized by additional IL-12 activation from up-regulated C1q [38] and C5a [39]. C3a 
also acts on TGFb [40] a fibrogenic interaction exemplified by up-regulation of Collagen 4.
C5a works through its receptor C5ar1, found in most renal cells [41]. Renal C5a acts on up-
regulated p-selectin (Selp) [42], which also amplifies complement activation [43] and may 
account for grievous clinical states [44]. Selp is also activated by C5b when integrated as the 
MAC [45]. Renal ICAM-1 was up-regulated in DI/DS rats, and it is shown as a downstream 
target for activation not only by C3ar1 [35] but also by C5ar1 [46]. In addition, C3a and C5a 
activate PI3K via independent pathways [47]. The gene encoding the co-stimulatory 
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receptor CD40 is also up-regulated in diabetic nephropathy, and it is shown interacting with 
both up-regulated C3a and C5a, suggesting that adaptive immunity, or a form of 
autoimmunity, might occur in diabetic nephropathy [31]. Some of these pro-inflammatory 
actions are mediated by up-regulated NFkB, which is a downstream target of both C3a and 
C5a [31], and may include up-regulated CD40 [48]. NFkB activates up-regulated CXCR4, 
suggesting a role for the CXCR4/CXCL12 signaling axis in diabetic nephropathy [49]. The 
network also shows NF-kB acting on up-regulated CCR2, a receptor involved in monocyte 
activation [50], on up-regulated CXCL1, the prototypical neutrophil chemokine [51], on up-
regulated CXCL10, a leukocyte chemoattractant [52], and on up-regulated CCL19, a 
chemokine for dendritic cells and T lymphocytes [53]. NF-kB, activated by IL1R, the 
receptor for IL-1 [54], acts on up-regulated collagen I gene, a redundant effect mediated by 
C3a, C5a, and IL-1 [55]. C5a also acts on the fibronectin gene [56], and presumably its 
cognate protein, which can then activate up-regulated BMP1 and promote the formation of 
collagens I and III [57]. C5a also acts on up-regulated TLR4 gene [58], potentially acting 
CASP1, which is required to cleave Pro-IL-1b and generate renal IL-1b, the master cytokine 
[59].
In conclusion, our data point to renal C3 activation in diabetic nephropathy of rats. C3 
reactivity in tubules leads to broader renal activation of the complement system, which is 
sustained by suppression of complement regulators, and contributes to renal inflammation, 
impaired function and fibrosis.
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Figure 1. ZS rat diabetic nephropathy
Representative renal sections (from top to bottom: Leder’s stain, Periodic acid Schiff (PAS) 
stain, and Masson’s trichrome stain) in the three groups of rats (from left to right, lean 
controls [lean], diabetic sham operated [DM/sham], and diabetic postischemic rats 
[Diabetes/Ischemia]) are presented. Leder’s stain (A) labeled clusters of leukocytes (pink), 
nearly absent in the Lean (LS) group, clearly present in Diabetes/Sham group (DS) and very 
prominent in Diabetes/Ischemia rats group (DI). The inset shows a neutrophil with typical 
nuclear morphology. PAS stain (B) demonstrated normal glomerular and tubular structures 
Kelly et al. Page 10
Am J Nephrol. Author manuscript; available in PMC 2016 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
in LS. The Diabetes/Sham group exhibited mild increases of interstitial and glomerular 
extracellular matrix, which were far more pronounced in the Diabetes/Ischemia group. 
Masson’s trichrome (C) stained connective tissue (blue) was normal in LS. Increases in 
connective tissue were evident in the glomeruli and interstitium of Diabetes/Sham group, 
and more severe in Diabetes/Ischemia group. Mean creatinine clearance and quantification 
of histological parameters are shown in the graphs (D-G). *p<0.05 vs LS; §p<0.05 vs DS, 
Scale bar=50 microns.
Kelly et al. Page 11
Am J Nephrol. Author manuscript; available in PMC 2016 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Complement system renal transcripts detected by RNAseq and RT2PCR
Transcript levels by RNAseq (A) are expressed as Reads per Kilobase Exon Model per 
Million mapped reads (RPKM, see text) and represent mRNAs encoding complement 
components (C1qa, C1s, C2–4, C6–9), as well as complement factor D (cfd), complement 
receptor type 2 (CR2) and c4 binding protein (C4b). These renal transcripts are significantly 
elevated in Diabetes/Sham and Diabetes/Ischemia groups. CD55, decay accelerating factor 
for complement, and CD59, encode complement regulatory proteins that limit the 
complement cascade. The two regulatory renal genes are suppressed in both Diabetes/Sham 
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and Diabetes/Ischemia groups. Significant correlations between transcript levels measured 
by RNAseq (horizontal axis) and quantitative PCR (QPCR) vertical axis are shown in B. 
These comparisons were made to verify the accuracy of the RNAseq determinations. To 
facilitate visualization on one axis, RNA Seq data are presented as follows: C1s/2, C2*2, 
C4/3, C6*10, C8*50, C9*10, cfd*100, CD55*3, CD59/10, CR2*50, C4b*10.
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Figure 3. Renal complement components in ZS rat diabetic nephropathy
Complement components 3, 4, and 9 are shown (A) in (Left to Right) Lean control rats 
(Control), Diabetic/Sham group (DM Sham) and Diabetes/Ischemia group (DM Isch). 
Complement (3,4,9) protein expression was barely detectable in the Lean control group, but, 
in contrast, was robustly expressed in the two diabetic groups. Similarly, glomerular C3 
levels (B) were nearly undetectable in the Lean group (Left), and rose prominently in the 
two diabetic groups (right). To examine complement generation in tubule cells, primary 
renal cells (C) were cultured in 38%O2 and 5% CO2 and transferred to 1%O2 and 5% CO2 
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for the designated times. The cells were then returned to 38%O2 and 5%CO2 for 24 hours. 
C3 mRNA was increased at 24 hours, whereas levels of immunoreactive C3 increased at 48 
hours of anoxia. Scale bar=50 microns; *p<0.05 vs time 0
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Figure 4. Complement system gene pathways in diabetic nephropathy
The numerical table on the upper left corner shows the fold changes in the different 
transcripts of the complement system. These values were all statistically significant 
(p<0.05). The network on the right upper corner contains up-regulated (red), inhibited (blue, 
italics) or unchanged transcripts (black). Green arrows show positive interactions. The main 
elements of this network were organized to show activation of the local classic and 
alternative pathways. The end result was the production of the anaphylatoxins C3a and C5a 
and the formation of the membrane attack complex (MAC). The bottom network delineates 
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critical interactions among the anaphylatoxins C3a and C5a with pro-inflammatory and pro-
fibrotic transcripts. These morbid interactions might be responsible, at least in part, for the 
development and eventual progression of diabetic nephropathy.
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